When things get really scary, investors don’t buy bitcoin, they buy gold, says Karen Maley in the Australian Financial Review. Last year was disappointing for gold, as inflation fears boost cryptocurrencies, dubbed “digital gold” by some, at the expense of the physical kind. Yet “the threat of an imminent European war” has pushed gold up 5% this month to $1,900/oz, an eight-month high. Meanwhile, bitcoin has fallen 20% so far this year. Gold has got an additional boost from “stronger physical demand”. Consumption in China, the world’s largest gold consumer, rose by more than a third last year amid a strong economic recovery from Covid-19.
Precious-metal mutual and exchange traded funds enjoyed five consecutive weeks of net inflows through 16 February, says Hardika Singh in The Wall Street Journal. A sign of strong investor interest, that is the longest streak since August 2020, when gold hit an all-time high of $2,067/oz.
It’s not just geopolitics that is pushing gold higher, says Neil Hume in the Financial Times. Investors are growing worried that upcoming hikes in US interest rates – needed to fight inflation – could go too far and tip the world’s biggest economy into recession. “There is an increasing sense that the Fed is significantly running behind the curve,” independent gold analyst Ross Norman tells the FT. “They might have to move quite aggressively and… therefore the chances of a policy error are getting increasingly large.”
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
If that happens then stocks will suffer, while gold could be a safe haven. “We would expect gold [ETF] inflows to accelerate as investors partly shift out of equities into gold,” says Mikhail Sprogis of Goldman Sachs, who thinks the price could reach new highs in the next few months.
-
Tesco braces for supermarket price war with rival AsdaTesco, Britain’s biggest grocer, has opted to cut its prices more quickly to prevent Asda grabbing market share
-
Supersonic travel: How China could 'leapfrog' US and Europe's commercial aviation industryOpinion Innovation in commercial aviation has been stuck for 60 years. A commercial supersonic jet might be back on the market soon, but will China get there first?
-
BP's 'long, painful decline' – and why next year could be even tougherOpinion Long-suffering shareholders in oil giant BP have been pushing for change. It won’t come soon enough, says Matthew Lynn
-
Investment trusts tap the profits in exotic and obscure global marketsOpinion Peter Walls, manager of the Unicorn Mastertrust fund, highlights three investment trusts as he shares where he'd put his money
-
Falling revenues and mounting debt spell trouble for Jumia TechnologiesStruggling African e-commerce platform Jumia Technologies looks headed for the exit, says Dr Matthew Partridge.
-
Next reports £1 billion in annual profits for the first time – what's next for the retailer?Clothing retailer Next has become only the fourth member of its sector to surpass £1 billion in annual profits. What does this mean for the company's future?
-
Best of British bargains: cash in on undervalued companies in the UK stock marketOpinion Michael Field, Chief Equity Market Strategist, EMEA, Morningstar, selects three attractive UK stocks where he'd put his money
-
Building firm Keller presents low debt and ample scope for growthGeotechnical contractor Keller, which supports vital global infrastructure, boasts rising profits and a cheap valuation
-
PZ Cussons share price down 75% in last decade – why it's one to watchOpinion Once-strong consumer-goods business PZ Cussons is out of favour with the market. That spells opportunity for investors, says Jamie Ward
-
Cash in on the biotech sector with specialist trust BioPharmaOpinion BioPharma has an attractive niche in lending to asset-rich biotechnology companies
